Riad Sherif
Chief Executive Officer presso OCULIS HOLDING AG
Patrimonio netto: 11 M $ in data 31/03/2024
Profilo
Riad Sherif is the founder of XPND Medical SA, which was founded in 2016.
He is currently the Chief Executive Officer & Director at Oculis SA, Oculis Holding AG, and Nexmed Plus SA. He is also an Independent Director at Revenio Group Oyj since 2022.
In his former positions, he served as the President & CEO-EMEA region at Alcon Finland OY, Director at European Biotech Acquisition Corp., President-Latin America Region at Novartis Corp., and Country Manager at Sanofi-Aventis Algérie SpA.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
OCULIS HOLDING AG
2.40% | 31/12/2023 | 878 486 ( 2.40% ) | 11 M $ | 31/03/2024 |
Posizioni attive di Riad Sherif
Società | Posizione | Inizio |
---|---|---|
REVENIO GROUP OYJ | Director/Board Member | 08/04/2022 |
OCULIS HOLDING AG | Chief Executive Officer | 01/12/2017 |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Chief Executive Officer | 01/01/2017 |
XPND Medical SA | Founder | 01/01/2016 |
Precedenti posizioni note di Riad Sherif
Società | Posizione | Fine |
---|---|---|
EURO BIOT | Director/Board Member | - |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Sanofi-Aventis Algérie SpA | Corporate Officer/Principal | - |
Alcon Finland OY | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
REVENIO GROUP OYJ | Health Technology |
OCULIS HOLDING AG | Health Technology |
Aziende private | 6 |
---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Alcon Finland OY | |
Sanofi-Aventis Algérie SpA | |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Commercial Services |
European Biotech Acquisition Corp.
European Biotech Acquisition Corp. Financial ConglomeratesFinance European Biotech Acquisition Corp. is a blank check company which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on January 8, 2021 and is headquartered in Lausanne, Switzerland. | Finance |
XPND Medical SA |
- Borsa valori
- Insiders
- Riad Sherif